Searched for: person:kistei01
CSF plasmablasts differentiate MS from other neurologic disorders [Letter]
Kister, I; Lotan, I; Wallach, A; Bacon, T; Cutter, G; Arbini, A
Multiparametric flow cytometry (FC) of CSF allows one to easily estimate the percentage of lymphocyte subpopulations in CSF. We hypothesized that an increased ratio of B-lineage cells in CSF of MS patients, as assessed with FC, could be useful for diagnostics. We analyzed CSF of 137 patients (70 MS, 24 infectious/autoimmune neurologic disorders (INDs), and 43 non-infectious/autoimmune neurologic disorders (NINDs)), and showed that CSF plasmablasts of >0.1% had a sensitivity of 40% for MS and specificity of 92% when comparing MS and IND, while plasmablasts of >0.25% had sensitivity of 36%, and 100% specificity.
PMID: 33383365
ISSN: 2211-0356
CID: 4762502
Improvements in patient-reported symptomscreen scores among ocrelizumab-treated patients with rrms: 2-year results from the casting clinical trial [Meeting Abstract]
Kister, I.; Cutter, G.; Buffels, R.; Clinch, S.; Kuenzel, T.; Vermersch, P.
ISI:000596547102130
ISSN: 1352-4585
CID: 4737222
A simple two-step test based on csf flow cytometry helps to discriminate ms from other inflammatory and noninflammatory neurologic disorders [Meeting Abstract]
Kister, I.; Lotan, I.; Wallach, A.; Bacon, T.; Cutter, G.; Arbini, A.
ISI:000596547101018
ISSN: 1352-4585
CID: 4735882
Pamrino: international mri and clinical data repository for neuromyelitis optica spectrum disorder [Meeting Abstract]
Chien, C.; Zimmermann, H.; Specovius, S.; Oertel, F. C.; Bichuetti, D.; Idagawa, M.; Altintas, A.; Tanriverdi, U.; Siritho, S.; Pandit, L.; D\Cunha, A.; Sa, M. J.; Figueiredo, R.; Tongco, C.; Qian, P.; Lotan, I.; Khasminsky, V.; Hellmann, M.; Stiebel-Kalish, H.; Rotstein, D.; Waxman, L.; Ontaneda, D.; Nakamura, K.; Abboud, H.; Subei, M. O.; Mao-Draayer, Y.; Havla, J.; Asgari, N.; Kister, I.; Rimler, Z.; Reid, A.; Ringelstein, M.; Broadley, S.; Arnett, S.; Marron, B.; Jolley, A.; Wunderlich, M.; Green, S.; Cook, L.; Yeaman, M.; Smith, T.; Brandt, A.; Skejo, P.; Silva, V. Cruz; Wuerfel, J.; Paul, F.
ISI:000596547100125
ISSN: 1352-4585
CID: 4735842
A longitudinal study of symptom botheration in Multiple Sclerosis
Kister, Ilya; Bacon, Tamar; Cutter, Gary R
BACKGROUND:It is well documented that ambulatory disability in MS worsens over time, but there is a dearth of information on symptom evolution in other domains commonly affected by MS. METHODS:SymptoMScreen (SyMS) is a validated tool for assessing symptom severity in 12 domains commonly affected by MS. Patients who attended two specialized MS centers filled out SyMS at each visit. We included in the study patients with neurologist-diagnosed MS who completed two SyMS questionnaires separated at least 12 months. We used the first and final assessment and adjusted for time on study, baseline SyMS score, age, sex, race, MS type, disability strata, and site. Changes over time were also examined using Markov chain estimates of moving from one level of botheration to another for each domain over 1-year periods. RESULTS:A total of 1,014 MS patients met the inclusion criteria. Mean composite SyMS score was 1.4 (±1.16) at baseline and increased by 0.084 (±0.73) points during 21.0 (±5.5) months of followup (p<0.0001). The initial mean composite SyMS score correlated strongly with the final mean composite SyMS score (r=0.81). Individual domain SyMS scores at baseline were highest for fatigue: 2.2 (±1.7), and lowest for vision: 1.1 (±1.3) and dexterity: 1.1 (±1.4). Small but significant increases during followup were seen in dexterity, bladder, vision, and pain domains, while significant decreases were seen in anxiety and sensory domains. We observed a high degree of inter-individual variability in symptom severity with the more extreme scores tending to resolve over time. CONCLUSIONS:Symptom botheration increases modestly year-to-year, as would be expected in a slowly progressive disease that evolves over decades. Initial symptom burden strongly correlated with final symptom burden, but there was a high degree of individual variability in symptom severity.
PMID: 33296981
ISSN: 2211-0356
CID: 4709012
Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey
Lotan, Itay; Bacon, Tamar; Kister, Ilya; Levy, Michael
BACKGROUND:Paroxysmal symptoms (PS), defined as short-lasting, recurrent, and stereotyped neurological symptoms, are frequently reported by patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). Their prevalence and spectrum of presentations in NMOSD have not been fully characterized. METHODS:Patients with NMOSD, who were members of a closed international Facebook Group, were recruited to complete an anonymous survey on REDCap. Participants were queried regarding demographic and NMOSD-related characteristics and PS history. RESULTS:The sample consisted of 219 responders with self-reported NMOSD, of whom 134 (63.8%) reported testing positive for AQP4 Antibody. 156 responders (71.9%) reported ≥1 type of PS during the disease course. The most common PS were intermittent tingling/numbness sensation (N=106, 67.9%), followed by involuntary muscle contractions/abnormal posture (N=95, 60.9%), hot/cold/burning sensations (N=87, 55.8%), and shock-like sensations along the spine or limbs (N=77, 49.4%). 150 responders (96% of those with PS) reported that PS were painful; in 82 responders (54.6%), the pain intensity reached ≥ 8/10 and in 40 responders (26.0%) - 10/10 level. PS were most commonly aggravated by fatigue (105 responders, 70.0%), physical activity (N=86, 57.3%), and neck flexion (N=39 responders, 26.0%). 82 patients (52.5% of those with PS) reported having been prescribed one or more medications for PS. Less than 50% reported them to be 'very helpful.' CONCLUSIONS:This survey highlights that PS occurs commonly in NMOSD patients. The symptomatology of PS is diverse. PS are often painful and not adequately treated. Our study represents a novel method to learn more about a rare disease from the patient's perspective. Given the fact that the study was conducted using an anonymous questionnaire and the diagnosis of NMOSD was self-reported by the survey participants, its' results should be regarded as a first step towards the understanding of PS in NMOSD, which should be further validated in a larger, controlled study.
PMID: 33223498
ISSN: 2211-0356
CID: 4676392
The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults
Parrotta, Erica; Kister, Ilya
PMCID:7509044
PMID: 33013639
ISSN: 1664-2295
CID: 4626602
Effectiveness of Subcutaneous Tocilizumab therapy in Neuromyelitis Optica Spectrum Disorder [Meeting Abstract]
Lotan, Itay; Charlson, Robert; Ryerson, Lana Zhovtis; Levy, Michael; Kister, Ilya
ISI:000536058004232
ISSN: 0028-3878
CID: 4561472
Lower Long-Term Disability with Early Start of High-Efficacy Therapies in Multiple Sclerosis [Meeting Abstract]
He, Anna; Merkel, Bernd; Brown, J. William; Ryerson, Lana Zhovtis; Kister, Ilya; Malpas, Charles; Horakova, Dana; Havrdova, Eva; Izquierdo Ayuso, Guillermo; Eichau Madueno, Sara; Lugaresi, Alessandra; Hupperts, R. M. M.; Sola, Patrizia; Ferraro, Diana; Butzkueven, Helmut; Grand-Maison, Francois; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Petersen, Thor; Grammond, Pierre; Granella, Franco; Van Pesch, Vincent; Bergamaschi, Roberto; Kalincik, Tomas
ISI:000536058002065
ISSN: 0028-3878
CID: 4561202
Improvement in Patient-Reported SymptoMScreen Scores Among Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Results From the CASTING Clinical Trial [Meeting Abstract]
Kister, Ilya; Cutter, Gary; Buffels, Regine; Clinch, Susanne; Wei, Wei; Vermersch, Patrick
ISI:000536058002135
ISSN: 0028-3878
CID: 4561252